Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer's pathology.

ABSTRACT:

Background

Blood-based biomarkers of Alzheimer's disease (AD) have become increasingly important as scalable tools for diagnosis and determining clinical trial eligibility. P-tau217 is the most promising due to its excellent sensitivity and specificity for AD-related pathological changes.

Methods

We compared the performance of two commercially available plasma p-tau217 assays (ALZpath p-tau217 and Janssen p-tau217+) in 294 individuals cross-sectionally. Correlations with amyloid PET and tau PET were assessed, and Receiver Operating Characteristic (ROC) analyses evaluated both p-tau217 assays for identifying AD pathology.

Findings

Both plasma p-tau217 assays were strongly associated with amyloid and tau PET. Furthermore, both plasma p-tau217 assays identified individua

SUBMITTER: Therriault J 

PROVIDER: S-EPMC10943661 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature